Back to Journals » Cancer Management and Research » Volume 12

RETRACTED ARTICLE: LncRNA MALAT1 Regulates the Progression and Cisplatin Resistance of Ovarian Cancer Cells via Modulating miR-1271-5p/E2F5 Axis

Authors Wang Y, Wang X, Han L, Hu D

Received 28 May 2020

Accepted for publication 3 September 2020

Published 12 October 2020 Volume 2020:12 Pages 9999—10010

DOI https://doi.org/10.2147/CMAR.S261979

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Sanjeev K. Srivastava



This paper has been retracted.

Wang Y, Wang X, Han L, Hu D. Cancer Manag Res. 2020;12:9999–10010.

At the authors request, the Editor and Publisher of Cancer Management and Research wish to retract the published article. The authors raised concerns over similarities between the flow cytometry data provided in Figures 2, 4 and 7 and indicated that it may have been fabricated. In addition, the authors advised that the cell migration and invasion data also provided in Figures 2, 4 and 7 was unreliable. The authors were unable to provide original data for their study and could not verify the reported findings. The Editor agreed with the authors decision to retract the article.

We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

Creative Commons License © 2020 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.